These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 36493574)

  • 1. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
    Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):717-729. PubMed ID: 38863432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
    Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.
    Kelkar SS; Prabhu VS; Zhang J; Ogando YM; Roney K; Verma RP; Miles N; Marth C
    Arch Gynecol Obstet; 2024 Jun; 309(6):2833-2841. PubMed ID: 38634898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
    Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.
    Tinker AV; Dhani NC; Ghatage P; McLeod D; Samouëlian V; Welch SA; Altman AD
    Ther Adv Med Oncol; 2023; 15():17588359231157633. PubMed ID: 36950270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
    Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
    Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for molecular subtypes of endometrial cancer in 2023.
    Karpel HC; Slomovitz B; Coleman RL; Pothuri B
    Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced and recurrent endometrial cancer: State of the art and future perspectives.
    Tronconi F; Nero C; Giudice E; Salutari V; Musacchio L; Ricci C; Carbone MV; Ghizzoni V; Perri MT; Camarda F; Gentile M; Berardi R; Scambia G; Lorusso D
    Crit Rev Oncol Hematol; 2022 Dec; 180():103851. PubMed ID: 36257537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
    Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Ta RM; Hecht JL; Lin DI
    Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
    Berton D; Pautier P; Lorusso D; Gennigens C; Gladieff L; Kryzhanivska A; Bowman J; Tian C; Cornfeld M; Van Gorp T
    Gynecol Oncol; 2024 Jul; 186():191-198. PubMed ID: 38824752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
    T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
    Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
    El-Ghazzi N; Durando X; Giro A; Herrmann T
    Onco Targets Ther; 2023; 16():359-369. PubMed ID: 37288137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker-driven therapy in endometrial cancer.
    Karpel H; Slomovitz B; Coleman RL; Pothuri B
    Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
    Oaknin A; Pothuri B; Gilbert L; Sabatier R; Brown J; Ghamande S; Mathews C; O'Malley DM; Kristeleit R; Boni V; Gravina A; Banerjee S; Miller R; Pikiel J; Mirza MR; Dewal N; Antony G; Dong Y; Zografos E; Veneris J; Tinker AV
    Clin Cancer Res; 2023 Nov; 29(22):4564-4574. PubMed ID: 37363992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.